Neuroendocrine neoplasms (NENs) and metastatic castration-resistant prostate cancer (mCRPC) are currently being treated with radioligand therapies (RLTs), a novel method of cancer treatment. People with breast, kidney, colon, or pancreatic cancer, have enormous potential to also be treated with this innovative therapy.
One of SPARC-Europe's objectives is to keep promoting the advantages of this treatment by widely disseminating stories about patients’ experiences, as patient education, awareness, and understanding of the treatment all remain barriers to RLT acceptance. Over the next two weeks, the Alliance will be releasing five new testimonials for their series of patient testimony videos, following the stories unveiled earlier this year.
The videos have been created in collaboration with the patient organisation International Neuroendocrine Cancer Alliance (INCA) and Steering Committee Member Dr. Ken Herrmann, featuring the testimonials of five neuroendocrine neoplasms patients: Barbara from Italy, Tomas from Sweden, Martin from Bulgaria, Joel from France and Volker from Germany.
Throughout their stories, patients outline their diagnoses and treatment pathway, their experience with RLT and the future they foresee for the treatment and NEN patients, wishing to shed light to policymakers and stakeholders on this therapy known for improving patients’ quality of life.
In the fifth of the five stories, Volker from Germany tells about his journey to neuroendocrine cancer diagnosis and comments on the radioligand therapy treatment he received. “My experience with RLT treatment was the most tolerable and the most goal-oriented treatment for me during my cancer journey”, said Volker, and wished it can be more intensely used with more patients in the EU. Volker expressed his gratitude to the Essen University Hospital for having allowed him to receive RLT treatment, for feeling well cared for, and for having been given constant and thorough medical advice. Watch the video to learn more!